Immunogenicity of Alternative Regimens of the Conjugated 7-Valent Pneumococcal Vaccine
Authors:
- David GreenbergDGDavid Greenberg
- Ron DaganRDRon Dagan
- 1 August 2010
- journal article
- research article
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 29 (8) , 756-762
Abstract
The 7-valent CRM197 pneumococcal conjugated vaccine (PCV7) was originally licensed using 3 primary doses during infancy and a booster in the second year of life. We compared the originally licensed regimen to 2 widely used alternative regimens. Five hundred forty-three infants were randomized to receive PCV7 at 2, 4, 6, and 12 months (3 + 1), at 4, 6, and 12 months (2 + 1), or at 2, 4, and 6 months (3 + 0). Blood was drawn at 2, 7, 13, and 19 months. Serotype-specific IgG concentrations were determined by ELISA. In the 2 + 1 group, postprimary IgG concentrations against serotypes 6B, 14, 18C, and 23F were reduced compared with the 3 + 1 or 3 + 0 groups. Both 3 + 1 and 2 + 1 groups showed marked booster response, but the 2 + 1 group had reduced concentrations against serotypes 6B, 18C, 23F. At 19 months, IgG antibodies decreased in both 3 + 1 and 2 + 1 groups but the 2 + 1 group had significantly lower concentrations against serotypes 6B, 18C, and 23F. IgG concentrations decreased in the 3 + 0 group during the second year and were significantly lower than those of 3 + 1 and 2 + 1 for all serotypes at 13 and 19 months. Significant differences in immunogenicity were documented between the reduced and the licensed regimens. The clinical implications of these differences require further studies.Keywords
This publication has 37 references indexed in Scilit:
- The Impact of Pneumococcal Conjugate Vaccine on Rates of Myringotomy With Ventilation Tube Insertion in AustraliaThe Pediatric Infectious Disease Journal, 2009
- Safety and immunogenicity of CRM197-conjugated pneumococcal–meningococcal C combination vaccine (9vPnC–MnCC) whether given in two or three primary dosesVaccine, 2008
- Efficacy of nine-valent pneumococcal conjugate vaccine against pneumonia and invasive pneumococcal disease in The Gambia: randomised, double-blind, placebo-controlled trialThe Lancet, 2005
- A Trial of a 9-Valent Pneumococcal Conjugate Vaccine in Children with and Those without HIV InfectionNew England Journal of Medicine, 2003
- Immunogenicity after one, two or three doses and impact on the antibody response to coadministered antigens of a nonavalent pneumococcal conjugate vaccine in infants of Soweto, South AfricaThe Pediatric Infectious Disease Journal, 2002
- Postlicensure evaluation of the effectiveness of seven valent pneumococcal conjugate vaccineThe Pediatric Infectious Disease Journal, 2001
- Efficacy of a Pneumococcal Conjugate Vaccine against Acute Otitis MediaNew England Journal of Medicine, 2001
- Safety and Immunogenicity of Heptavalent Pneumococcal Vaccine Conjugated to CRM197 in United States InfantsPediatrics, 1998
- Safety and immunogenicity of tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides conjugated to either tetanus toxoid or diphtheria toxoid in young infants and their boosterability by native polysaccharide antigensThe Pediatric Infectious Disease Journal, 1997
- Infant Immunization with Pneumococcal CRM $_{197}$ Vaccines: Effect of Saccharide Size on Immunogenicity and Interactions with Simultaneously Administered VaccinesThe Journal of Infectious Diseases, 1997